Related Experiment Videos
[When should mitral valve prolapse be considered a real disease?]
1Service de cardiologie, CHU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges, France.
Annales De Cardiologie Et D'Angeiologie
|January 31, 2003
Summary
Mitral valve prolapse (MVP) affects 1.3% of the population. Key complications include mitral regurgitation and infective endocarditis, requiring prompt medical attention for better patient outcomes.
Area of Science:
- Cardiology
- Valvular Heart Disease
Context:
- Mitral valve prolapse (MVP) is defined by specific echocardiographic criteria.
- Understanding MVP prevalence and associated risks is crucial for clinical management.
Purpose:
- To define diagnostic criteria for mitral valve prolapse.
- To report the prevalence of MVP in the general population.
- To outline potential complications and their associated risks.
Summary:
- MVP is diagnosed when mitral leaflets displace >2mm superiorly with leaflet thickness ≥5mm.
- Prevalence is 1.3% in the general population, with equal distribution between sexes.
- Complications include mitral regurgitation (requiring surgical repair), infective endocarditis (higher risk in older men with murmurs), arrhythmias, and rare neurologic events or sudden death.
Impact:
- Establishes clear diagnostic criteria for MVP.
- Highlights the significant risk of complications, guiding proactive patient monitoring and intervention.
- Informs clinical practice regarding the management of MVP patients, particularly concerning surgical repair and endocarditis prophylaxis.